BioSpace News Archive

Simulations Plus, Inc. reported financial results for its 2019 fiscal year and fourth quarter ended August 31, 2019.

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that it has received minutes from pre- New Drug Application meetings with the Food and Drug Administration for the acute treatment of migraine for Qtrypta.

China Biologic Products Holdings, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, announced its unaudited financial results for the third quarter of 2019.

Study shows that Apple Watch app can identify heart rhythm irregularities, which can help catch atrial fibrillation.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share.

Ritter Pharmaceuticals, Inc. reported recent business developments and financial results for the three and nine months ended September 30, 2019.

Halozyme Therapeutics, Inc., a biotechnology company focused on novel biological and drug delivery approaches, announced the pricing of $400.0 million aggregate principal amount of its convertible senior notes due 2024

Built for clinical operations professionals by clinical operations professionals, SureClinical today announced the launch and availability of its Spring 2019 Suite for ClinOps™.

CareCentrix, the leading provider of in home-based post-acute-care solutions, put out a statement today in support of CT2030, Connecticut Governor Ned Lamont’s comprehensive transportation infrastructure plan.

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.